Ito K, Omae T, Ikeda M, Iimura O, Yoshinaga K, Ishii M, Kaneko Y, Mizuno Y, Masuyama Y, Takeda T
Yohkaichi National Hospital, Japan.
Drugs. 1988;36 Suppl 1:18-24. doi: 10.2165/00003495-198800361-00005.
To clarify the antihypertensive effect, safety and clinical usefulness of ketanserin, a comparative double-blind study was carried out in 277 patients with essential hypertension using propranolol as a control drug. Ketanserin 10 to 30 mg twice daily and propranolol 20 to 40 mg 3 times daily were administered for 12 weeks. The results showed no difference in antihypertensive effect and clinical usefulness between the drugs. In the ketanserine group, plasma concentration of total cholesterol was decreased significantly, and the reduction in heart rate was less than in the propranolol group. These findings suggest that ketanserin may satisfactorily control blood pressure.
为阐明酮色林的降压效果、安全性及临床实用性，以普萘洛尔作为对照药物，对277例原发性高血压患者进行了一项比较双盲研究。每日两次给予酮色林10至30毫克，每日三次给予普萘洛尔20至40毫克，给药12周。结果显示，两种药物在降压效果和临床实用性方面无差异。在酮色林组，总胆固醇的血浆浓度显著降低，心率降低幅度小于普萘洛尔组。这些发现表明，酮色林可能令人满意地控制血压。
